The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection

Digestive Diseases and Sciences

Volumn 57, Issue 5, 2012, Pages 1271-1280

  Buob, David ^a,b,c   Fauvelc, Harold ^c   Truant, Stéphanie ^a,b   Wacrenier, Agnès ^a   Buisine, Marie Pierre ^a,b,c   Mariette, Christophe ^a,b,c   Copin, Marie Christine ^a,b,c   Porchet, Nicole ^a,b,c   Leteurtre, Emmanuelle ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIV LILLE   (France)

Author keywords

Colon cancer; Intratumoral heterogeneity; Laser microdissection; Metastasis process; Mucins

Indexed keywords

CTNNB1 PROTEIN; K RAS PROTEIN; MUCIN; ONCOPROTEIN; PROTEIN ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MICROSATELLITE DNA; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRATUMORAL HETEROGENEITY; LASER MICRODISSECTION; LIVER METASTASIS; MALE; MICROSATELLITE INSTABILITY; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; ADENOCARCINOMA; COLON; COLON TUMOR; COMPARATIVE STUDY; GENETICS; GENOTYPING TECHNIQUE; LASER CAPTURE MICRODISSECTION; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; UTILIZATION REVIEW;

ADENOCARCINOMA; AGED; BETA CATENIN; COLON; COLONIC NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENOTYPING TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LIVER NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863622555     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-2023-1     Document Type: Article

References (33)

1. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss; 2002.
2. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
3. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138-141.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
5. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21:497-503.
6. Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature. 2002;418:823.
7. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526-3535.
8. D'Arrigo A, Belluco C, Ambrosi A, et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer. 2005;115:256-262.
9. Kaplan RN, Rafii S, Lyden D. Preparing the ''soil'': the premetastatic niche. Cancer Res. 2006;66:11089-11093.
10. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77-99.
11. Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest. 1991;87:1037-1045.
12. Baldus SE, Mönig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology. 2002;40:440-449.
13. Jang KT, Chae SW, Sohn JH, Park HR, Shin HS. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. J Korean Med Sci. 2002;17:29-33.
14. Leteurtre E, Gouyer V, Rousseau K, et al. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell. 2004;96: 145-151.
15. Truant S, Bruyneel E, Gouyer V, et al. Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer. 2003;104: 683-694.
16. Leteurtre E, Zerimech F, Piessen G, et al. Relationships between mucinous gastric carcinoma, MUC2 expression and survival. World J Gastroenterol. 2006;12:3324-3331.
17. Copin MC, Buisine MP, Leteurtre E, et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol. 2001;32:274-281.
18. Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48:1597-1602.
19. Hamilton SR, Vogelstein B, Kudo S, et al. Carcinoma of the colon and the rectum. In: Hamilton SR, Aaltonen LA, eds. Tumours of the Digestive System. Lyon, France: IARC Press; 2000:105-119.
20. Hovenberg HW, Davies JR, Herrmann A, Lindén CJ, Carlstedt I. MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj J. 1996;13:839-847.
21. Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2004;17:150-157.
22. Wickström C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J. 1998;334:685-693.
23. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.
24. Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 1996;56:3331-3337.
25. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122:61-69.
26. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403-410.
27. You JF, Hsieh LL, Changchien CR, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res. 2006;12: 4244-4250.
28. Biemer-Hüttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res. 2000;6:1909-1916.
29. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol. 1996;49: 560-564.
30. Matsuda K, Masaki T, Watanabe T, et al. Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. Jpn J Clin Oncol. 2000;30:89-94.
31. Kuwabara A, Watanabe H, Ajioka Y, et al. Alteration of p53 clonality accompanying colorectal cancer progression. Jpn J Cancer Res. 1998;89:40-46.
32. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 2001;93:346-352.
33. Fukunari H, Iwama T, Sugihara K, Miyaki M. Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis. Surg Today. 2003;33:408-413.